Why the study?
Does angiographic slow/no-flow during PCI predict adverse outcomes in patients with acute myocardial infarction?
Does angiographic slow/no-flow during PCI predict adverse outcomes in patients with acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Lesion length and admission blood glucose predict slow/no-flow during PCI for AMI, which in turn strongly predicts 1-year MACCE and cardiac death.
OBJECTIVE: In patients with acute myocardial infarction (AMI), angiographic slow/no-flow during percutaneous coronary intervention (PCI) may lead to unfavorable outcomes. The aim of our study was to investigate the predictors and long-term prognosis of AMI patients with angiographic slow/no-flow. METHODS: We evaluated 228 consecutive AMI patients with either normal flow (Thrombolysis in Myocardial Infarction [TIMI] flow grade 3)(n=192) or slow/no-flow (< or =TIMI-2)(n=36) based on cineangiograms performed during PCI. RESULTS: Multivariable analysis demonstrated that a long lesion (> or =10 mm)(odds ratio [OR], 3.514; 95% confidence interval [CI], 1.505-8.206; p=0.004) and acute hyperglycemia (> or =180 mg/dl)(OR, 3.011; 95% CI, 1.211-7.485; p=0.018) were significant and independent predictors of angiographic slow/no-flow. Further, we found that there was a high correlation (89%) for predicting angiographic slow/no-flow when the optimal cut-off values of lesion length (10.45 mm) and blood glucose levels on admission (187.5 mg/dl) were combined as identified by analysis of the receiver operating characteristic curves. One-year mortality and incidence of major adverse cardiac and cerebrovascular events (MACCE) were significantly higher in the slow/no-flow group than that in the normal flow group. Angiographic slow/no-flow was independently predictive of MACCE (hazard ratio [HR], 3.642; 95% CI, 1.208-10.980; p=0.022) and cardiac death (HR, 5.287; 95% CI, 1.155-24.204; p=0.032). CONCLUSIONS: Lesion length and blood glucose level on admission can be used to stratify AMI patients into a lower or higher risk for angiographic slow/no-flow before optimal coronary intervention. In addition, angiographic slow/no-flow predicts an adverse outcome in AMI patients.
No takes yet. Share an insight, caveat, or question.
Suenari et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: